secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2026-05-20T20:04:03+00:00
Accession:  0001193125-26-232533
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CMS expands Medicare coverage for Personalis's NeXT Personal test to monitor neoadjuvant therapy in breast cancer
--------------------------------------------------------------------------------

- New coverage applies to monitoring treatment response to neoadjuvant therapy in Stage II-III TNBC or HER2+ breast cancer patients.
- Expansion effective May 19, 2026, under CMS Molecular Diagnostics Program.
- NeXT Personal is an ultrasensitive liquid biopsy test; this indication broadens addressable patient population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312526232533/0001193125-26-232533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312526232533/psnl-20260519.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-232533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer